Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | Thymosin Alpha-1 is a powerful immune system booster. Whether you are fighting a bad virus, a chronic illness, or just getting sick too often, it flips the immune system on full blast to clear the threat. | Thymalin acts like a drill sergeant for your immune system. It trains your immune cells to fight off viruses and keeps your body's defenses acting young, strong, and highly organized. |
Studied For | Chronic hepatitis B treatmentChronic hepatitis C treatmentCancer immune adjunct therapyVaccine adjuvantSepsis / severe infectionCOVID-19 immune support researchImmunodeficiency modelsHIV / AIDS immune supportAntifungal immune supportMalignant melanoma adjuvantLung cancer immune researchT-cell / NK cell activationDendritic cell maturationToll-like receptor signalingAutoimmune modulationGut mucosal immunityChemotherapy immune protectionimmune boosterT-cell modulationviral infectionautoimmuneimmunomodulatorLyme diseasechronic fatiguecancer adjunctivevaccine efficacy | Immunosenescence reversalImmune system restoration in agingInfection resistance enhancementT-cell function restorationLongevity via immune optimizationAge-related immune declineCancer immune surveillance researchHIV immune support modelsChronic infection modelsThymus involution reversalAutoimmune modulation researchAntioxidant protectionMelatonin-thymalin longevity combinationimmune regulationanti-agingT-cell functionlongevityviral infectionsimmune restoration |
Research Areas | ImmuneLongevityGut Health & GI RepairPain & Inflammation | LongevityImmune |
Best Stacked With | ll-37thymalinglutathionekpvbac-water | thymosin-alpha-1epithalonll-37glutathionebac-water |
Overview | ||
Category | Immunity & Wellness | Anti-Aging & Longevity |
Compound Class | 28-amino acid peptide; N-terminal fragment of prothymosin alpha; biological response modifier | Polypeptide thymic bioregulator derived from calf thymus tissue |
Molecular Target | TLR2/TLR9 signaling; dendritic cell maturation; T-helper (Th1) polarization; NK cell cytotoxicity; NF-kB immunomodulation | T-lymphocyte differentiation and maturation; thymic hormones (thymosin, thymopoietin analog); IL-2 / IFN-gamma restoration |
Aliases / AKA | ThymalfasinZadaxinTalpha1Tα1Thymosin alpha 1Thymosin α1 | Thymus polypeptide bioregulatorThymalin peptideThymus bioregulatorThymus extract bioregulatorKhavinson thymus peptideThymulin analog |
Parent Compound | Prothymosin alpha N-terminal fragment | Calf thymus extract |
Molecular Weight | 3108.3 Da | complex / ~333 Da for Glu-Trp |
Amino Acid Sequence | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH | thymus polypeptide complex (identity ambiguous; some vendors list dipeptide Glu-Trp) |
CAS Number | 62304-98-7 | No single registry CAS (multi-peptide thymic extract; confirm per certificate of analysis) |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 962 Good | 293 Good |
Clinical Trials | 4141 Active | Not Listed |
Regulatory Status | Approved as thymalfasin in 30+ countries; not US central-approved. | Used in Russia; not US or EU approved; research chemical. |
Evidence & Regulatory | ||
Half-Life | ~2 hours | ~15 minutes |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | The most clinically validated peptide in this group: more than 20 human trials and approval in over 30 countries for hepatitis B and C and as a cancer immune adjunct. | Russian elderly-cohort studies report improved T-cell counts and, in long follow-ups, reduced infections. Largely single-lineage and older; preliminary. |
Side Effects Noted | Generally well tolerated; injection-site reactions are most common; serious adverse events are uncommon. | Reported well tolerated in Russian clinical use; no robust modern adverse-event dataset; possible immunogenicity from a tissue-extract product. |
Warnings | Not centrally US FDA or EMA approved (off-label/investigational in the US, subject to FDA compounding action). Caution in transplant immunosuppression and autoimmunity. | Not FDA or EMA approved; extract composition can vary by source; caution in autoimmunity. Research use only. Vendor identity (extract vs Glu-Trp dipeptide) should be confirmed. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | supplied or sterile diluent | bacteriostatic or sterile water |
Storage Temp | refrigerate 2-8C, dark; do not freeze the formulated product | frozen/refrigerated, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | N-acetyl group aids stability. | Short-lived constituents. |
Reconstituted Shelf Life | 14 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
